Your browser doesn't support javascript.
loading
Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction.
Nicolas, Johny; Beerkens, Frans; Cao, Davide; Sartori, Samantha; Pivato, Carlo Andrea; Qiu, Hanbo; Giustino, Gennaro; Chiarito, Mauro; Claessen, Bimmer E; Zhang, Zhongjie; Nardin, Matteo; Razuk, Victor; Jones, Davis; Camaj, Anton; Power, David; Banashefski, Bryana; Sweeny, Joseph; Baber, Usman; Dangas, George; Sharma, Samin K; Kini, Annapoorna; Mehran, Roxana.
Afiliação
  • Nicolas J; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Beerkens F; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Cao D; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sartori S; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Pivato CA; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Qiu H; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy.
  • Giustino G; IRCCS Humanitas Research Hospital, Manzoni 56, Rozzano, 20089, Milan, Italy.
  • Chiarito M; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Claessen BE; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Zhang Z; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Nardin M; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy.
  • Razuk V; IRCCS Humanitas Research Hospital, Manzoni 56, Rozzano, 20089, Milan, Italy.
  • Jones D; Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Camaj A; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Power D; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Banashefski B; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sweeny J; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Baber U; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Dangas G; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sharma SK; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kini A; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Mehran R; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
J Thromb Thrombolysis ; 53(1): 20-29, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34347202
ABSTRACT
Patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) are at increased risk for thrombotic and bleeding complications compared to patients with chronic coronary syndrome (CCS). The academic research consortium (ARC) recently suggested a set of criteria to identify patients at high bleeding risk (HBR). We sought to evaluate the performance of the ARC-HBR criteria among patients undergoing PCI according to clinical presentation. We included all consecutive patients undergoing PCI at a tertiary-care center. Patients were deemed at HBR if they fulfilled ≥ 1 major or ≥ 2 minor ARC-HBR criteria. The primary bleeding endpoint was a composite of in-hospital or post-discharge bleeding at 1-year follow-up. Secondary outcomes included all-cause death and myocardial infarction. Out of 6068 patients, 1391 (22.9 %) presented with AMI and were more often at HBR than those with CCS (46.9 % vs. 43.0 %, p = 0.01). HBR patients had a higher risk for the primary bleeding endpoint than non-HBR, irrespective of the clinical indication for PCI (AMI 19.5 % vs. 5.5 %; HR 3.86, 95 % CI 2.63-5.69; CCS 6.8 % vs. 2.6 %; HR 2.65, 95 % CI 1.92-3.68; p-interaction = 0.11). Secondary outcomes followed a similar trend. After multivariable adjustment, AMI presentation remained significantly associated with increased risk for bleeding at 1 year (HR 1.64, 95 % CI 1.13-2.38, p = 0.01). The ARC-HBR criterion associated with the highest bleeding risk was severe/end-stage chronic kidney disease in AMI and moderate/severe anemia in CCS. The ARC-HBR framework successfully identified AMI and CCS patients with increased risk for bleeding complications at 1 year post-PCI. Figure prepared with BioRender.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Intervenção Coronária Percutânea / Infarto do Miocárdio Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Intervenção Coronária Percutânea / Infarto do Miocárdio Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article